10^th International Conference on Liver Diseases & Hepatology December 02-03, 2019 Tokyo, Japan

Biography:

Abstract:

Tetracarpidium conophorum is a tropical plant used in Nigerian ethno pharmacological system of medicine for treating various diseases including hepatic ailments. The present study was designed to investigate bioassay guided isolation of hepatoprotective compounds from T. conophorum seeds in carbon tetrachloride (CCl₄) induced liver damage. Powdered seeds of T. conophorum were macerated in methanol for 72 hrs. The methanol extract was partitioned into n-hexane(HE), dichloromethane(DCM) and ethyl acetate (EA) fractions. The methanol extract and fractions were tested in-vivo for their hepatotoprotective activities in CCl₄ rats model.The most active HE and EA fractions were subjected to column chromatography led to the isolation of nine known compounds respectively, Betulinic acid(1), β-sitosterol(2), sitosterol-3-O-[ β –D glucopyranoside](3), stimagsterol(4), ricinine(5),α-amyrin(6), gallic acid(7), keampferol(8),  apigenin(9). All compounds were identified by UV, IR, MS and NMR spectroscopy.

Biography:

Dr. Ramon M. Corpuz has completed his PhD from The University of Tokyo. He is the pathologist of Liminal R&D BioSciences Inc (fka Prometic Biosciences Inc.). He served as a diligent and dependable veterinary/toxicologic/preclinical pathologist of GLP and non-GLP toxicology and pharmacology non-clinical studies (100+ studies) for more than 10 years. He is a member of the Society of Toxicologic Pathology with an American College of Veterinary Pathologists board eligibility, a member of the Charles Louis Davis DVM Foundation for the Advancement of Veterinary Pathology, 2007-2009, a board of director of the Philippine College of Veterinary Pathology, 1998-2000, and a member of the Japanese Veterinary Science Society, 1990-1994. He was a former Monbusho Scholar of the Japanese Government, 1987-1994, a scholar of the International Congress of Virology, 1993 (Glasgow, UK), and a scholar of the Philippine Veterinary Drug Association, 1981-1982.

Abstract:

Chronic liver diseases are a major cause of mortality and morbidity worldwide. Liver fibrosis is characterized by progressive accumulation of extracellular matrix proteins, resulting in destruction of the hepatic architecture.  This study investigates the effect of anti-fibrotic/metabolic compound PBI-4050 on NASH and liver fibrosis using three animal models. C57BL/6 mice were fed with either a standard or a high-fat diet for 14 weeks and treated with PBI-4050 (200 mg/kg, oral once a day) for an additional six weeks. Liver fibrosis was induced by 10% CCl₄ in (2 mL/kg), twice a week for 8 weeks. Mice were treated from day 1 to 58 with oral administration of PBI-4050 (200 mg/kg). Bile duct ligation (BDL) was performed on male Wistar rats on day 0 and treated with PBI-4050 (200 mg/kg) (day 1 to 21). 

Biography:

Attila Toth has completed his PhD at the age of 48 years from University of Pécs. He is the leading researcher in the Metabolic control and Bioimpedance Research Group. He has published more than 60 papers. Attila is currently investigating the early detection of liver fats and possible solutions to the detection of hepatic fibrosis and liver carcinoma based on bioimpedance measurement.

Abstract:

The non alcoholic fatty liver disease (NAFLD), with high risk for cardiovascular pathology and the development of metabolic syndrome, involves 25% of the adult population. The progressive version of NAFLD 1eads to cirrhosis and hepatocellular carcinoma. Considering the necessity of life style change, it is conceviable that the earliest diagnosis is an utmost imperative. The procedures employed in the nowdays clinical praxis in the field are either invasive (biopsy) or their usage is greatly limited for the (extremely) obese patients (Ultrasound, CT, MR). A well known limitation for the Fibroscan measurements in obese patients is their thick subcutaneous fat deposit. It is, therefore, a great need to gain a relatively low cost, brand new type of portable measuring device for bedside use: a non-invasive, low frequency spectrum bioimpedance measuring device that we developed recently appears to be an appropriate candidate for this purpose. Due to inventing the necessary developments in our bioimpedance measuring device, liver fibrosis will be possible to non-invasibly determine even in those patients whose diagnosis could only be made so far by the histological analysis of their biopsy samples.

This is why our research team, using the experience gained in detecting liver fats, envisages developing a new type of non-invasive test method capable of early stage (less than 20%) liver fats and liver fibrosis detect. The effectiveness of a measuring device that can be used for medical practice is enhanced by a clinically accurate body composition measurement procedure, which currently not available.

Biography:

Abstract:

Biological mechanisms that control liver regeneration remain poorly defined. However, these mechanisms are remarkable issues in the clinic that affect management of hepatic loss caused by liver surgery, traumatic injury, chronic infection, or liver poisoning. Increasing evidence has shown that various growth factors, cytokines, and metabolic signaling pathways affect the liver regenerative process. Our aim is to study the effect of bromodomain and extraterminal (BET) protein inhibition on liver regeneration and its mechanism. We studied the role of BET protein inhibitor, JQ1, in liver regeneration in a mouse model after 70% partial hepatectomy (PH). We evaluated yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) and Notch signaling pathways, which were affected by BET protein inhibitor in mouse hepatic tissues in vivo and AML12 cell lines in vitro. We evaluated the role of YAP/TAZ signaling pathway inhibition in liver regeneration in a mouse model after 70% PH. Moreover, we analyzed the relationship of YAP/TAZ and Notch signaling pathways via overexpression or RNA silencing of YAP in AML12 cells. Moreover, we used YAP overexpression mouse model to examine whether it can rescue liver regeneration damage caused by inhibition of BET proteins.

Biography:

Abstract:

The prevalence of obesity has increased over the years and some of the patients with hepatocellular carcinoma (HCC) are obese. In order to examine any effect of obesity on the behavior of HCC, we scrutinized medical records of our obese HCC patients. HCC patients with body mass index (BMI) of greater than 27 kg / m2 were included in this retrospective study and their clinical, laboratory and radiological parameters noted.The total number of patient is 52; 37 were male and 15 female. The median age of the patients was 55 years (range 33-93). The etiology of HCC was HCV 34.6%, HBV 17%, HDV 1.9%, NAFLD 30%, others (5.7%). Their median BMI was 31.9 (27.1-43.5). Alphafetoprotein was 9.1 (1.1-8937). Twenty-two (42%) patients were of Child A class and rest Child B or C. HCC was involving the right lobe in 30 (58%), left lobe in 13 (25%) and both lobes in 9 (17%) patients. Most of the obese HCC patients were middle age males with HCV related HCC followed by NAFLD as etiological factors. A comparative study with non-obese HCC is underway.

Biography:

Mahreen’s research is to develop new strategies to identify the structure of virulence factors – usually proteins – present in MDR bacteria, which will help the development of new and more effective drugs to combat them. Medicines, often of poor quality in Pakistan , are frequently used excessively and are a major factor in an increase in multidrug resistance (MDR) in bacterial diseases - an issue that particularly impacts women. As a member of NAYS and Tanzeem-E-Khidmat-Khalaq Association, she participated in awareness campaigns on women education in different villages, so that they send their daughters /wives for higher education. 

Abstract:

Cirrhosis is a life threatening disease that end up with Hepatocellular carcinoma or end stage liver cancer ,the relationship of HCV, HBV with liver cirrhosis and its contribution in development of HCC To study the prevalence of HBV and HCV  among admitted patients in KPK in KTH (Khyber teaching hospital) related to liver cirrhosis and prognosis.

A retrospective study is carried out in which 415 patients are diagnosed from Medical units of different hospitals in Peshawar from April 2012- January 2014.Inclusion criteria was patients with HCV and HBV positive along with liver cirrhosis, both male and female and age group above 15years. . Out of 415, male were 212 and female 203 and patients mostly effected were of age between 16-80 year with mean age of 52. Third generation ELISA protocol was carried out to diagnose Hepatitis-C and Hepatitis-B virus in which male 49.2% and females 39.2% HCV positive followed by HBV positive in male 27.8 % and female 24.7%. Other possible risk factors include Alcohol in 47.1% male and 0 in female , Diabetes 36% male and 20.2% female, Wilson’s disease 0.9% male and 0.5% female and obesity 6.66% and 11.3% in male and female respectively. Complications such as Ascites, Encephalopathy, Hematemasis, Anaemia are more likely to be seen.

Biography:

Marwa Elfaoymy has completed his PhD from Menoufia University. She is Assitant Lecture In Hepatology & gastroenterology department. 

Abstract:

Acute variceal bleeding in liver cirrhosis is an immediate life-threatening condition and a major complication of portal hypertension. We aimed to study the predictors of mortality in acute variceal bleeding in cirrhotic patients.We prospectively evaluated 703 consecutive patients admitted with endoscopically proven acute variceal hemorrhage (71.4% males, mean age 58 ± 10.3 years), 43% admitted with first attack of hematemesis, 14.1% Child-Turcotte-Pugh (CTP) A, 47.2% CTP B, 38.7% CTP C, 38.3% had HCC. All patients received antibiotics and vasoactive drugs. Endoscopic treatment was individualized. The outcome was the 6-week mortality. Bleeding was controlled in 422 patients (59.9%) and 210 patients died (29.8%), (122 (17.4%) during hospitalization, 69 patients from causes not related to the acute hemorrhage (9.8%)). Rebleeding occurred in 281 patients (39.9%) after the first week.Disease severity scores (platelet-albumin-bilirubin (P-ALBI), ALBI, MELD, IMELD, MELD-Na, and UMELD) and bleeding risk scores (GB score, admission Recall, AIMS 65 and APASL score) were calculated on admission and the full Recall score following endoscopy. Demographic, clinical and laboratory data and the calculated scores were compared between survivors and non-survivors

Biography:

Marwa Elfaoymy has completed his PhD from Menoufia University. She is Assitant Lecture In Hepatology & gastroenterology department. 

Abstract:

Acute variceal bleeding in liver cirrhosis is an immediate life-threatening condition and a major complication of portal hypertension. We aimed to study the predictors of mortality in acute variceal bleeding in cirrhotic patients.We prospectively evaluated 703 consecutive patients admitted with endoscopically proven acute variceal hemorrhage (71.4% males, mean age 58 ± 10.3 years), 43% admitted with first attack of hematemesis, 14.1% Child-Turcotte-Pugh (CTP) A, 47.2% CTP B, 38.7% CTP C, 38.3% had HCC. All patients received antibiotics and vasoactive drugs. Endoscopic treatment was individualized. The outcome was the 6-week mortality. Bleeding was controlled in 422 patients (59.9%) and 210 patients died (29.8%), (122 (17.4%) during hospitalization, 69 patients from causes not related to the acute hemorrhage (9.8%)). Rebleeding occurred in 281 patients (39.9%) after the first week.Disease severity scores (platelet-albumin-bilirubin (P-ALBI), ALBI, MELD, IMELD, MELD-Na, and UMELD) and bleeding risk scores (GB score, admission Recall, AIMS 65 and APASL score) were calculated on admission and the full Recall score following endoscopy. Demographic, clinical and laboratory data and the calculated scores were compared between survivors and non-survivors